Appointment of Members of Senior Executive Service Performance Review Board, 20304 [2025-08404]
Download as PDF
<![CDATA[
20304
Federal Register / Vol. 90, No. 91 / Tuesday, May 13, 2025 / Notices
Only intervenors have the right to seek
rehearing of the Commission’s decision
and be heard by the courts if they
choose to appeal the Commission’s final
ruling. An intervenor formally
participates in the proceeding by filing
a request to intervene pursuant to Rule
214 of the Commission’s Rules of
Practice and Procedures (18 CFR
385.214). Motions to intervene are more
fully described at https://www.ferc.gov/
resources/guides/how-to.asp. Please
note that the Commission will not
accept requests for intervenor status at
this time. You must wait until the
Commission receives a formal
application for the project, after which
the Commission will issue a public
notice that establishes an intervention
deadline.
Additional Information
Additional information about the
project is available from the
Commission’s Office of External Affairs,
at (866) 208–FERC, or on the FERC
website (www.ferc.gov) using the
eLibrary link. Click on the eLibrary link,
click on ‘‘General Search’’ and enter the
docket number in the Docket Number
field. Be sure you have selected an
appropriate date range. For assistance,
please contact FERC Online Support at
FercOnlineSupport@ferc.gov or toll free
at (866) 208–3676, or for TTY, contact
(202) 502–8659. The eLibrary link also
provides access to the texts of formal
documents issued by the Commission,
such as orders, notices, and
rulemakings.
Public meetings or site visits will be
posted on the Commission’s calendar
located at https://www.ferc.gov/newsevents/events along with other related
information.
Dated: May 7, 2025.
Carlos D. Clay,
Deputy Secretary.
[FR Doc. 2025–08365 Filed 5–12–25; 8:45 am]
BILLING CODE 6717–01–P
EXECUTIVE OFFICE OF THE
PRESIDENT
ddrumheller on DSK120RN23PROD with NOTICES1
Office of National Drug Control Policy
Appointment of Members of Senior
Executive Service Performance Review
Board
Office of National Drug Control
Policy (ONDCP).
ACTION: Notice of appointments.
AGENCY:
The following persons have
been appointed to the ONDCP Senior
Executive Service Performance Review
Board: Ms. Michele Marx (as Chair), Ms.
SUMMARY:
VerDate Sep<11>2014
18:08 May 12, 2025
Jkt 265001
Debbie Seguin, Ms. Shannon Kelly, and
Mr. Kemp Chester.
FOR FURTHER INFORMATION CONTACT:
Please direct any questions to Anthony
Jones, Acting General Counsel, (202)
881–8862, Office of National Drug
Control Policy, Executive Office of the
President, Washington, DC 20503.
Authority: 5 U.S.C. 4314(c)(1)
Dated: May 8, 2025.
Anthony Jones,
Acting General Counsel.
[FR Doc. 2025–08404 Filed 5–12–25; 8:45 am]
BILLING CODE 3280–F5–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–R–138 and
CMS–10882]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
Contents
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
July 14, 2025.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–R–138 Medicare Geographic
Classification Review Board
Procedures and Criteria
CMS–10882 Part C and Part D
Medicare Prescription Payment Plan
Model Documents
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
AGENCY:
SUMMARY:
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\13MYN1.SGM
13MYN1
]]>Agencies
[Federal Register Volume 90, Number 91 (Tuesday, May 13, 2025)]
[Notices]
[Page 20304]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-08404]
=======================================================================
-----------------------------------------------------------------------
EXECUTIVE OFFICE OF THE PRESIDENT
Office of National Drug Control Policy
Appointment of Members of Senior Executive Service Performance
Review Board
AGENCY: Office of National Drug Control Policy (ONDCP).
ACTION: Notice of appointments.
-----------------------------------------------------------------------
SUMMARY: The following persons have been appointed to the ONDCP Senior
Executive Service Performance Review Board: Ms. Michele Marx (as
Chair), Ms. Debbie Seguin, Ms. Shannon Kelly, and Mr. Kemp Chester.
FOR FURTHER INFORMATION CONTACT: Please direct any questions to Anthony
Jones, Acting General Counsel, (202) 881-8862, Office of National Drug
Control Policy, Executive Office of the President, Washington, DC
20503.
Authority: 5 U.S.C. 4314(c)(1)
Dated: May 8, 2025.
Anthony Jones,
Acting General Counsel.
[FR Doc. 2025-08404 Filed 5-12-25; 8:45 am]
BILLING CODE 3280-F5-P
